Drugs / Mesenchymal stem cell
Mesenchymal stem cell
also known as
MSC · bone marrow derived mesenchymal stem cells · BM-MSC · MSCs · Mesenchymal Stromal Cell · stem cell transplantation · BMMSCs · LMSCs · +24 more
Trials 72 · started per year
today
1
7
3
2
5
3
6
6
3
4
5
2
6
7
3
3
3
2
1
2004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00813267 | Dec 2009 → Aug 2011 | osteonecrosis | Jianming Tan | Unknown | No outcome recorded |
| Phase 120 trials | ||||||
| Phase 1 | NCT05443464 | Jun 2023 → Jun 2024 | acute graft versus host disease | Ossium Health, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT05407766 | Aug 2022 → Apr 2024 | anal fistula | Ossium Health, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT05095532 | Dec 2021 → Jun 2027 expected | chronic pancreatitis | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 1 | NCT04236479 | Jul 2020 → Dec 2026 expected | congenital heart disease | Catherine Bollard | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03929120 | Nov 2019 → Jul 2021 | connective tissue disorder, interstitial lung disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02443961 | Apr 2019 → Apr 2020 | bronchopulmonary dysplasia | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Completed | No outcome recorded |
| Phase 1 | NCT03371329 | Dec 2017 → Oct 2020 | intracerebral hemorrhage | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02600130 | Oct 2016 → Sep 2020 | Alzheimer disease | Longeveron Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03069170 | Jul 2016 → Sep 2020 | multiple sclerosis | Stem Cells Arabia | Unknown | No outcome recorded |
| Phase 1 | NCT02490020 | Jan → Dec 2016 | disease related to solid organ transplantation, transplant rejection | Qipeng Sun | Unknown | No outcome recorded |
| Phase 1 | NCT02344849 | Jul 2015 → Jan 2018 | erectile dysfunction | Pharmicell Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02327832 | Dec 2014 → Mar 2017 | — | Yamaguchi University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02181712 | Jul 2014 → Aug 2021 | transplant rejection, transplant-related bronchiolitis obliterans | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01759784 | Mar 2014 → Mar 2017 | amyotrophic lateral sclerosis | Royan Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT01775774 | Jul 2013 → Feb 2014 | acute respiratory distress syndrome | Michael A. Matthay | Completed | No outcome recorded |
| Phase 1 | NCT01725698 | Nov 2012 → Dec 2014 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 1 | NCT01440309 | Nov 2011 → Nov 2013 | primary biliary cholangitis | Robert Chunhua Zhao, MD, PhD | Unknown | No outcome recorded |
| Phase 1 | NCT01436058 | Sep 2010 → Sep 2011 | osteoarthritis | Royan Institute | Completed | No outcome recorded |
| Phase 1 | NCT01499056 | Jun 2010 → Feb 2011 | osteoarthritis, hip | Royan Institute | Completed | No outcome recorded |
| Phase 1 | NCT00850187 | Aug 2008 → Jul 2010 | osteoarthritis, knee | Royan Institute | Completed | No outcome recorded |
| Phase 1/223 trials | ||||||
| Phase 1/2 | NCT05939167 | Dec 2023 → Jul 2027 expected | AIDS | Cell Energy Life Sciences Group Co. LTD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05433298 | May → Nov 2022 | COVID-19, pneumonia | Paulo Brofman | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04565665 | Jul 2020 → Oct 2026 expected | COVID-19, acute respiratory distress syndrome, cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03460795 | Jun 2020 → Mar 2025 | cirrhosis of liver | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03863002 | Oct 2019 → Oct 2021 | liver failure | Tianjin Weikai Bioeng., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03460223 | Apr 2018 → Mar 2020 | renal fibrosis | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03525418 | Feb 2018 → Jun 2024 | hypoplastic left heart syndrome | Longeveron Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03484741 | Apr 2017 → Nov 2018 | type 1 diabetes mellitus | Van Hanh General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02982915 | Nov 2016 → Sep 2021 | — | Longeveron Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02116634 | May 2015 → May 2017 | amyotrophic lateral sclerosis | Alzahra Hospital, Iran | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02644759 | Feb 2014 → Aug 2017 | type 1 diabetes mellitus | Stem Cells Arabia | Completed | No outcome recorded |
| Phase 1/2 | NCT02641769 | Jan 2014 → Jun 2030 expected | azoospermia | Stem Cells Arabia | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01877759 | Dec 2013 → Dec 2014 | cirrhosis of liver | Chaitanya Hospital, Pune | Unknown | No outcome recorded |
| Phase 1/2 | NCT01844063 | Jul 2013 → Jan 2016 | liver failure | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01446640 | Oct 2011 → Jun 2013 | spinal cord injury | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase 1/2 | NCT01446614 | Oct 2011 → Jun 2013 | Parkinson disease | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase 1/2 | NCT01412593 | Sep 2011 → Sep 2012 | liver failure | King Saud University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01305694 | Feb 2011 → Jun 2012 | aplastic anemia | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase 1/2 | NCT01322789 | Sep 2008 → Nov 2015 | type 1 diabetes mellitus | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 1/2 | NCT00702741 | Jun 2008 → Sep 2011 | — | Mesoblast, Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT00659217 | May 2008 → May 2010 | lupus nephritis | Organ Transplant Institute, China | Unknown | No outcome recorded |
| Phase 1/2 | NCT00659620 | May 2008 | chronic transplant rejection | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00646724 | Jan 2008 → Jan 2012 | type 1 diabetes mellitus | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT07284641 | May 2026 → May 2030 expected | DiGeorge syndrome, GATA2 deficiency with susceptibility to MDS/AML, Omenn syndrome, STAT3-related early-onset multisystem autoimmune disease +8 | Paul Szabolcs | Recruiting | No outcome recorded |
| Phase 2 | NCT07544537 | Sep 2024 → Jan 2026 overdue | erectile dysfunction | National Scientific Medical Center, Kazakhstan | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02587572 | Dec 2023 | metabolic disease | Longeveron Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04925024 | Jun 2021 → Jun 2026 overdue | hypoplastic left heart syndrome | Longeveron Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02814864 | Apr 2021 → Apr 2022 | radiation cystitis, radiation proctitis | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT03362424 | Nov 2020 → Dec 2023 | disease of the tendon, rotator cuff syndrome | University of Sao Paulo | Suspended | No outcome recorded |
| Phase 2 | NCT04594850 | Oct 2020 → Jan 2026 | erectile dysfunction | Pharmicell Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04501354 | Aug → Dec 2020 | osteoporosis | Ahmad Jabir Rahyussalim | Unknown | No outcome recorded |
| Phase 2 | NCT04315987 | Jun 2020 → Feb 2021 | pneumonia | Azidus Brasil | Completed | No outcome recorded |
| Phase 2 | NCT03164083 | Nov 2019 → Aug 2020 | osteoarthritis | SCARM Institute, Tabriz, Iran | Withdrawn | No outcome recorded |
| Phase 2 | NCT03917797 | Apr 2019 → Dec 2024 | lupus nephritis, systemic lupus erythematosus | Universidad de los Andes, Chile | Unknown | No outcome recorded |
| Phase 2 | NCT04499105 | Jul 2017 → Dec 2020 | intervertebral disk degenerative disorder | Ahmad Jabir Rahyussalim | Unknown | No outcome recorded |
| Phase 2 | NCT03169231 | Jul 2017 → Sep 2021 | — | Longeveron Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04493918 | May 2017 → Dec 2020 | tuberculosis, spinal | Ahmad Jabir Rahyussalim | Unknown | No outcome recorded |
| Phase 2 | NCT02112500 | Feb 2014 → Dec 2016 | adult acute respiratory distress syndrome | Asan Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02140528 | Aug 2013 → Mar 2016 | — | Royan Institute | Completed | No outcome recorded |
| Phase 2 | NCT01504464 | Oct 2012 → Sep 2015 | osteoarthritis, knee | Royan Institute | Completed | No outcome recorded |
| Phase 2 | NCT01741090 | Sep 2009 → Jun 2013 | alcoholic liver cirrhosis | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT00972660 | Sep 2009 → Dec 2015 | chronic graft versus host disease | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04545307 | Nov → Dec 2019 | chronic apical periodontitis, dental pulp necrosis | Universidad Central de Venezuela | Completed | No outcome recorded |
| Phase 2/3 | NCT02448849 | Jun 2015 → Apr 2017 | disease of bone structure | Royan Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT01526850 | Feb 2012 → Dec 2013 | chronic graft versus host disease | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06097780 | Jun 2024 → Sep 2025 | Huntington disease | Azidus Brasil | Unknown | No outcome recorded |
| Phase 3 | NCT01652209 | Sep 2013 → Aug 2024 | acute myocardial infarction | Pharmicell Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07400458 | Mar 2022 → Oct 2028 expected | acute myocardial infarction | Pharmicell Co., Ltd. | Recruiting | No outcome recorded |
| — | NCT02414295 | Aug 2013 → Aug 2014 | Klinefelter syndrome, azoospermia | Man Clinic for Andrology, Male Infertility and Sexual Dysfunction | Completed | No outcome recorded |
| — | NCT01499459 | Jun 2008 → Jul 2012 | cirrhosis of liver | University of Health Sciences Gulhane Faculty of Medicine | Unknown | No outcome recorded |
| — | NCT00187018 | Mar 2004 → Aug 2007 | osteogenesis imperfecta | St. Jude Children's Research Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04629105 Comparator | Jul 2020 → Jun 2024 | COVID-19, acute respiratory distress syndrome | Longeveron Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT02266394 Comparator | Oct 2014 → Sep 2020 | chronic kidney disease, ischemic disease, renal artery disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00955669 Comparator | Aug 2009 → Aug 2010 | — | Third Military Medical University | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01849887 Comparator | Jan 2016 | ischemic stroke | University of California, Irvine | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00644410 Comparator | Sep 2008 → Mar 2015 | congestive heart failure | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 1/2 | NCT00260338 Comparator | Dec 2005 → Jul 2009 | coronary artery disorder, myocardial ischemia | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04520945 Comparator | Oct 2020 → Sep 2021 | osteoarthritis, knee | Meluha Life Sciences SDN BHD | Unknown | No outcome recorded |
| Phase 2 | NCT02513238 Comparator | Aug 2015 → Apr 2017 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01392105 Comparator | Mar 2007 → May 2010 | acute myocardial infarction | Yonsei University | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-19 | Takeda | Takeda’s Phase 3 AURORA Study Provides Evidence of Maribavir’s Clinically Meaningful and Durable Effect in Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint takeda.com ↗ |
| 2016-12-06 | AbbVie | Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant abbvie.com ↗ |
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 91 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mesenchymal stem cell | “In particular, mesenchymal stem cell (MSC) transplantation has been applicated in the clinic for treat several human diseases such as liver injury and liver fibrosis displayed...” NCT03460795 ↗37“mesenchymal stem cell (MSC) transplantation has been applicated in the clinic for treat several human diseases” NCT03460223 ↗ “intraventricular injection of mesenchymal stem cell by stereotaxis” NCT01759784 ↗ “bone marrow derived cultured MSC (mesenchymal stem cell)” NCT03371329 ↗ “intra articular inection of mesenchymal stem cell” NCT01499056 ↗ |
| Known as | Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01775774 ↗ |
| Known as | BM-MSC | “We first compared long-term clinical outcomes in treating critical limb ischemia (CLI) and foot ulcer in patients with diabetes between autologous bone marrow mesenchymal stem...” PMID 30917698 ↗ Mar 20195“The investigators will evaluate safety and efficacy of percutaneous implantation of autologous BM-MSC (bone marrow -derived mesenchymal stromal cell) in combination with PL...” NCT02448849 ↗ “autologous bone marrow-derived mesenchymal stem cells (BM-MSC)” NCT03484741 ↗ |
| Known as | BMD-MSCs | “Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)” NCT03929120 ↗ |
| Known as | BMMSCs | “combination of bone marrow-derived mesenchymal stem cells (BM-MSCs), hydroxyapatite (HA) granules, bone morphogenetic protein-2 (BMP-2), and internal fixation for treating CSDs.” PMID 30747273 ↗ Feb 20192“cultured autologous bone marrow derived mesenchymal stem cells (BM-MSCs)” NCT01436058 ↗ “autologous bone-marrow derived mesenchymal stromal cells (BMMSCs)” PMID 24211066 ↗ Oct 2013 |
| Known as | BMSC | “Autologous Bone marrow-derived Mesenchymal Stem Cells (BMSC)” NCT07544537 ↗ |
| Known as | bone marrow -derived mesenchymal stromal cell | “The investigators will evaluate safety and efficacy of percutaneous implantation of autologous BM-MSC (bone marrow -derived mesenchymal stromal cell) in combination with PL...” NCT02448849 ↗ |
| Known as | bone marrow derived mesenchymal stem cells | “The patients with nonunion fracture who underwent percutaneous implantation of bone marrow derived mesenchymal stem cells in combination with platelet lysate product.” NCT02448849 ↗ |
| Known as | bone marrow derived mesenchymal stromal/stem cell | “Percutaneous implantation of autologous bone marrow derived mesenchymal stromal/stem cell in combination with PL will be done in 30 patients with tibia nonunion.” NCT02448849 ↗ |
| Known as | Bone Marrow Mesenchymal stem cells | “autologous transplantation of Bone Marrow Mesenchymal stem cells (MSCs) mixed with collagen I scaffold” NCT00850187 ↗ |
| Known as | Bone marrow transplant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00187018 ↗ |
| Known as | Cellgram-ED | “Cellgram-ED is autologous bone marrow-derived mesenchymal stem cells ex vivo expanded for approximately 30 days.” NCT02344849 ↗ |
| Known as | Chondrogen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04520945 ↗ |
| Known as | Hearticellgram-AMI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01652209 ↗ |
| Known as | Hematopoietic stem cell transplant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284641 ↗ |
| Known as | hMSCs | “Human bone marrow-derived mesenchymal stem (stromal) cells (hMSCs) improve survival in mouse models of acute respiratory distress syndrome (ARDS)” PMID 24891325 ↗ Jun 2014 |
| Known as | human MSCs | “a phase 1/2 trial of bone marrow-derived human MSCs for moderate-severe ARDS.” PMID 25593740 ↗ Jul 2014 |
| Known as | laromestrocel | “We conducted a randomized, dose-finding clinical trial to test whether human bone marrow-derived allogeneic mesenchymal stem cells (MSCs; laromestrocel) improve physical...” PMID 41747733 ↗ Feb 2026 |
| Known as | LMSCs | “This is a Phase I, prospective, randomized, placebo-controlled, double-blinded study designed to test the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) for...” NCT02600130 ↗2“evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome” NCT02587572 ↗ “Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)” NCT03169231 ↗ |
| Known as | Lomecel-B | “This study is designed to assess the safety, tolerability, and efficacy of Lomecel-B (formerly LMSCs) as an adjunct therapy to the standard stage II (BDCPA) surgical...” NCT03525418 ↗2“Each subject will be intravenously infused with 100 million Lomecel-B (formerly LMSCs) or placebo on Day 0.” NCT04629105 ↗ |
| Known as | Longeveron Mesenchymal Stem Cells | “evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome” NCT02587572 ↗ |
| Known as | Longeveron Mesenchymal Stem Cells (LMSCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02982915 ↗ |
| Known as | mesenchymal stem (stromal) cells | “Human bone marrow-derived mesenchymal stem (stromal) cells (hMSCs) improve survival in mouse models of acute respiratory distress syndrome (ARDS)” PMID 24891325 ↗ Jun 20141“human allogeneic bone marrow-derived mesenchymal stem/stromal cells” PMID 38114796 ↗ Dec 2023 |
| Known as | mesenchymal stem cells | “mesenchymal stem cells (MSCs) are collected from autologous bone marrow mononuclear cells” NCT03484741 ↗1“allogeneic, bone marrow (BM) derived mesenchymal stem cells (MSC)” NCT03371329 ↗ |
| Known as | Mesenchymal Stromal Cell | “autologous bone-marrow derived mesenchymal stromal cells (BMMSCs)” PMID 24211066 ↗ Oct 2013 |
| Known as | mesenchymal stromal cells | “mesenchymal stromal cells (MSCs) from a related donor” PMID 23731760 ↗ Jul 2013 |
| Known as | MSC | “Mesenchymal stem cells (MSC) are grown from a person's own fat tissue (obtained as a fat biopsy) and infused back into the patient's own kidney.” NCT02266394 ↗13“Effectiveness and Safety of Mesenchymal Stem Cell (MSC) Implantation on Degenerative Discus Disease Patients” NCT04499105 ↗ “mesenchymal stem cell (MSC) had an effect to prevent rejection and DGF after renal transplantation” NCT02490020 ↗ “Mesenchymal Stem Cells (MSCs) have been shown to have immunosuppressive and repairing properties.” NCT00813267 ↗ “Mesenchymal Stem Cell (MSC) has been shown to have immunosuppressive and repairing properties.” NCT00659217 ↗ “Mesenchymal Stem Cell (MSC) has been shown to have immunosuppressive and repairing properties.” NCT00659620 ↗ “autologous mesenchymal stem cell (MSC) transplantation” NCT01499459 ↗ “Mesenchymal Stromal Cell (MSC) injections” NCT02814864 ↗ “Experimental:Mesenchymal stem cell(MSC).” NCT00972660 ↗ “Mesenchymal Stem Cell (MSC) therapy” NCT02443961 ↗ |
| Known as | MSCs | “bone marrow (BM)-derived mesenchymal stem cells (MSCs) transplanted in patients with OA of the knee, ankle, or hip” PMID 26058927 ↗ Jun 20155“Mesenchymal stem cells (MSCs) with potent anti-inflammatory, regenerative and immune-modulatory properties” PMID 29514693 ↗ Mar 2018 “delivery of mesenchymal stem/stromal cells (MSCs) has already been translated to human subjects with RAS” PMID 34183258 ↗ Jun 2021 “autologous transplantation of Bone Marrow Mesenchymal stem cells (MSCs) mixed with collagen I scaffold” NCT00850187 ↗ “Mesenchymal Stem Cells (MSCs) have been shown to have immunosuppressive and repairing properties.” NCT00813267 ↗ “mesenchymal stromal cells (MSCs) from a related donor” PMID 23731760 ↗ Jul 2013 |
| Known as | NestaCell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04315987 ↗ |
| Known as | OSSM-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05407766 ↗ |
| Known as | Stem cell transplant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01412593 ↗ |
| Known as | stem cell transplantation | “intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation” NCT03164083 ↗ |
| Known as | UC-MSCs | “human umbilical-cord-derived MSCs (UC-MSCs) via the peripheral vein before renal transplantation” PMID 29514693 ↗ Mar 2018 |
| Action | Inhibit | “MSCs can fully suppress T cell function” NCT01305694 ↗ |
| Modality | Cell therapy | “autologous mesenchymal stem cell therapy” NCT00260338 ↗ |
| Route | Other | “another infusion of bone marrow cells” NCT00187018 ↗ |